다발성 골수종

150개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved150 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-B-cell maturation antigen (BCMA, Anti-B-cell maturation antigen, Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells)

Myeloma, Plasma-Cell; Myeloma-Multiple · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited Datastale920th Hospital of Joint Logisti…Phase 2

Anti-GPRC5D CAR-T cells infusion (Anti-GPRC5D CAR-T cells infusion)

Multiple Myeloma in Relapse; Multiple Myeloma, Refractory · GPRC5D

#GPRC5D#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleBristol-Myers SquibbPhase 1

Anti-Signaling lymphocytic activation molecule F7 (SLAMF7, Anti-Signaling lymphocytic activation molecule F7, Anti-Signaling lymphocytic activation molecule F7 (SLAMF7) chimeric antigen receptor (CAR) T cells)

Myeloma-Multiple; Myeloma, Plasma-Cell · Myeloma-Multiple

#Myeloma-Multiple#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleLuminary TherapeuticsPhase 1

Autologous CAR-T cell therapy expressing the BAFF-ligand. (Autologous CAR-T cell therapy expressing the BAFF-ligand.)

Multiple Myeloma, Refractory; Multiple Myeloma in Relapse · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleZhejiang UniversityPhase 1

BCMA Targeted CAR T-cells (BCMA Targeted CAR T-cells)

Relapse Multiple Myeloma; Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleThe Pregene (ShenZhen) Biotechn…Phase 1

BCMA nanobody CAR-T cells (BCMA nanobody CAR-T cells)

Relapsed/Refractory Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChongqing Precision Biotech Co.…Phase 2

BCMA targeted prime CAR-T cells (BCMA targeted prime CAR-T cells)

Multiple Myeloma; Neoplasm, Plasma Cell · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

BCMA-CS1 cCAR T cells (BCMA-CS1 cCAR T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

BCMA-PD1-CART Cell (BCMA-PD1-CART Cell)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.50 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

0.75 x10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (0.75 x10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

1 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (1 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedical College of WisconsinPhase 1

2.5 x 10^6 cells/kg (BCMA-TGFβ CAR-T cells, BCMA-TGFβ CAR-T cells (2.5 x 10^6 cells/kg))

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleCells & Genes Biotech (Shanghai…Phase 1

BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell (BCMA-Targeted Chimeric Antigen Receptor Autologous T-cell)

Relapsed/Refractory; Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleBioray LaboratoriesPreclinical

BCMA-UCART (BCMA-UCART)

Multiple Myeloma · BCMA

#BCMA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Discontinued
CGTLimited DatastaleHebei Yanda Ludaopei HospitalPhase 1

BCMA/CD19 dual-target CAR-T cell immunotherapy (BCMA/CD19 dual-target CAR-T cell immunotherapy)

Multiple Myeloma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

BCMA/GPRC5D CAR-T cells (BCMA/GPRC5D CAR-T cells)

Multiple Myeloma; Multiple Myeloma in Relapse · BCMA

#BCMA#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBiohaven Pharmaceuticals, Inc.Phase 1

BHV-1100 plus cytokine induced memory-like (CIML, BHV-1100 plus cytokine induced memory-like, BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active

4 / 8 pages

← PreviousNext →